Live Sessions
| GENETICS OF NEURODEGENERATION 1 | 08:30 - 10:30 | JOIN |
| INDIVIDUAL CELL TYPES< ORGANOIDS AND ANIMAL MODELS IN AD PD (1) MECHANISTIC & TRANSLATIONAL ASPECTS | 08:30 - 10:30 | JOIN |
| TAU-TARGETED TREATMENT STRATEGIES | 08:30 - 10:30 | JOIN |
| FLUID BIOMARKERS 1 | 08:30 - 10:30 | JOIN |
| OPENING CEREMONY AND AWARDS | 11:00 - 11:30 | JOIN |
| PLENARY LECTURE 1: REGULATION OF SYNAPTIC FUNCTION BY ALZHEIMER’S ASSOCIATED GENES | 11:30 - 12:00 | JOIN |
| PLENARY LECTURE 2: FLUID AND PET IMAGING BIOMARKERS FOR ALZHEIMER’S AND PARKINSON’S DISEASES | 12:00 - 12:30 | JOIN |
| PLENARY LECTURE 3: KEY MILESTONES IN ALZHEIMER’S DISEASE | 12:30 - 13:00 | JOIN |
| The future of AD and PD – reaching beyond symptom control -Supported by Novo Nordisk | 14:00 - 15:40 | JOIN |
| The time is Now: The Importance of Early Detection and Diagnosis of Alzheimer’s Disease- Supported by Biogen | 15:45 - 16:15 | JOIN |
| PATHOLOGICAL CELLULAR NICHES ABETA STRUCTURE AMYLOID PLAQUES AND NEURODEGENERATION | 16:15 - 18:15 | JOIN |
| MICROGLIA TREM2 NEUROINFLAMMATION | 16:15 - 18:15 | JOIN |
| GENETICS OF NEURODEGENERATION 2 | 16:15 - 18:15 | JOIN |
| FORUM ON:ANTI-TAU APPROACHES IN CLINICAL TRIALS | 17:30 - 18:30 | JOIN |
| FORUM ON:BLOOD-BASED BIOMARKERS COMPARISON TO FLUID-BASED BIOMARKERS IMAGING AND ASSESSMENT OF DIAGNOSTIC & TREATMENT EFFECTS TREATMENT EFFECT: HOW TO MEASURE MINIMAL CLINICAL EFFICACY? | 18:30 - 19:30 | JOIN |
| PLENARY LECTURE 4: DISEASE MODIFICATION IN PD: WHAT ARE THE PROMISING TARGETS? | 08:30 - 09:00 | JOIN |
| CHOLINERGIC MECHANISMS IN AD AND PD | 09:10 - 11:10 | JOIN |
| CLINICAL TRIALS DESIGN HETEROGENEITY OF SYMPTOMS RESPONSE TO TREATMENT DIAGNOSTICS IMAGING AND BIOMARKERS IN AD FTLD | 09:10 - 11:10 | JOIN |
| SINGLE-CELL GENOMICS STEM CELLS 3 | 09:10 - 11:10 | JOIN |
| DISEASE MECHANISMS PATHOPHYSIOLOGY: ASTROCYTES MICROGLIA IMMUNE PROTECTION | 09:10 - 11:10 | JOIN |
| Amyloid related imaging abnormalities - from clinical trials to clinical practice: a practice-based discussion-Supported by Biogen | 11:40 - 13:25 | JOIN |
| ALPHA-SYNUCLEIN AND DISEASE MECHANISMS | 14:45 - 16:45 | JOIN |
| APOE: MECHANISMS AND TREATMENT STRATEGIES 1 | 14:45 - 16:45 | JOIN |
| DISEASE MECHANISMS INFLAMMATION. MICROGLIA ASTROCYTES AMYLOIDS | 14:45 - 16:45 | JOIN |
| How can the use of Alzheimer’s Disease diagnostic biomarkers in clinical practice help identify appropriate patients for future Disease Modifying Therapy? - Supported by Eli Lilly | 14:45 - 23:59 | JOIN |
| FORUM ON:TRANSLATIONAL DRUG DISCOVERY IN PD/ LBD PHASE I-III - RECENT UPDATES | 15:50 - 16:50 | JOIN |
| MRI 1 | 17:15 - 19:15 | JOIN |
| Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease? | 17:15 - 19:15 | JOIN |
| CONGOPHILIC AMYLOID ANGIOPATHY (CAA) VASCULAR DEMENTIA VASCULAR DAMAGE IN DEMENTIA BLOOD-BRAIN BARRIER ARIA | 17:15 - 19:15 | JOIN |
| APOE MECHANISMS AND TREATMENT STRATEGIES 2 | 17:15 - 19:15 | JOIN |
| PLENARY LECTURE 5: TAU AND DIVERSITY OF DRIVERS IN ALZHEIMER DISEASE | 08:30 - 09:00 | JOIN |
| Novel approaches in AD: Cutting Edge Science Diagnostic and Therapeutic Strategies-Supported by Grifols | 09:10 - 11:10 | JOIN |
| TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS IN AD | 09:10 - 11:10 | JOIN |
| FTD ALS; C9ORF72 TDP-43 AND PROGRANULIN | 09:10 - 10:55 | JOIN |
| ALPHA-SYNUCLEIN- DISEASE MECHANISMS DETECTION & THERAPEUTIC RELEVANCE | 09:10 - 11:10 | JOIN |
| Alzheimer's disease - Let's ADdress it together - Supported by Roche | 11:40 - 13:25 | JOIN |
| Balancing innovation and access: how do we optimize a standard of care and equity in Alzheimer’s? | 12:15 - 13:25 | JOIN |
| Where does our hope come from in Alzheimer’s disease? | 12:15 - 13:25 | JOIN |
| ABETA TARGETING THERAPIES IN AD 1 | 14:45 - 16:45 | JOIN |
| TAU PROPAGATION AND CELLULAR INTERACTIONS 1 | 14:45 - 16:45 | JOIN |
| FLUID BIOMARKERS 3 | 14:45 - 16:45 | JOIN |
| Diagnostic Framework for the use of PET and SPECT imaging agents in Alzheimer’s disease and other dementias-Supported by GE Healthcare | 14:45 - 23:59 | JOIN |
| FORUM ON:PHASE I-III IN AD: MORE THAN TWO TARGETS? | 15:50 - 16:50 | JOIN |
| ABETA TARGETING THERAPIES IN AD 2 | 17:15 - 19:15 | JOIN |
| GLUCOCEREBROSIDASE LRRK2-PD AND ALPHA-SYNUCLEIN | 17:15 - 19:15 | JOIN |
| MRI 2 | 17:15 - 19:15 | JOIN |
| ALPHA-SYNUCLEIN PD ANIMAL MODELS MECHANISTIC ASPECTS AND THERAPEUTIC STRATEGIES | 17:15 - 19:15 | JOIN |
| PLENARY LECTURE 6: MICROGLIAL TAM RECEPTORS IN ALZHEIMER’S DISEASE | 08:30 - 09:00 | JOIN |
| AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 4 | 09:10 - 11:10 | JOIN |
| TAU PROPAGATION AND CELLULAR INTERACTIONS 2 | 09:10 - 11:10 | JOIN |
| AD LBD DIAGNOSIS IMAGING & CLINICAL TRIALS | 09:10 - 11:10 | JOIN |
| Brain Entry and Exit Routes for Cells and Molecules - Supported by Cure Alzheimer’s Fund | 09:10 - 23:59 | JOIN |
| FLUID BIOMARKERS 5 | 14:45 - 16:45 | JOIN |
| ADVANCES IN PD AND LBD DRUG DEVELOPMENT 1 | 14:45 - 16:45 | JOIN |
| TAUPATHIES: MECHANISMS & TREATMENT STRATEGIES 2 | 14:45 - 16:45 | JOIN |
| Gut microbiota and Parkinson’s disease: Implications for pathogenesis and treatment-Supported by Green Valley | 14:45 - 23:59 | JOIN |
| FORUM ON:AMYLOID-REMOVING THERAPIES: THE BEGINNING OT THE END OR THE END OF THE BEGINNING? | 15:50 - 16:50 | JOIN |
| DIAGNOSTIC ACCURACY IMAGING AND FLUID BIOMARKERS IN AD PD LBD | 17:15 - 19:15 | JOIN |
| BACE-1 BACE-2 PRESENILIN GAMMA-SECRETASE. TACE AND APP PROCESSING & Abeta TRUNCATION TOXICITY | 17:15 - 19:15 | JOIN |
| AD HETEROGEINITY DIAGNOSTIC AIDS AND CLINICAL TRIALS | 17:15 - 19:45 | JOIN |
| COINCIDENT NEURODEGENERATIVE DISEASE AMYLOID TAU TDP-43 PATHOLOGY | 17:15 - 19:15 | JOIN |
| PLENARY LECTURE 7: STOMPING OUT THE SPARK: TARGETING PYROGLU3 AMYLOID-BETA FOR THE TREATMENT OF ALZHEIMER’S DISEASE | 08:30 - 09:00 | JOIN |
| COVID-19 IMPACT ON NEURODEGENERATIVE DISEASES | 09:05 - 10:50 | JOIN |
| BRAIN GUT INTERACTIONS MICROBIOME | 09:05 - 11:05 | JOIN |
| ABETA AND OTHER TARGETING THERAPIES IN AD | 09:05 - 11:05 | JOIN |
| ADVANCES IN PD AND LBD DRUG DEVELOPMENT 2 | 11:35 - 13:20 | JOIN |
| SEX AND GENDER IN NEURODEGENERATIVE DISEASES | 11:35 - 13:35 | JOIN |
| RESILIENCE AND VULNERABILITY FACTORS RISK ASSESSMENT PREVENTION CLINICAL TRIALS | 11:35 - 13:35 | JOIN |
| FORUM ON:TRANSLATIONAL DRUG DISCOVERY: THE VALUE OF ANIMAL MODELS ORGANOIDS DIGITAL AI | 11:35 - 12:35 | JOIN |
| FORUM ON:COVID-19 AND THE BRAIN | 12:40 - 13:40 | JOIN |
